Ace Investor Mukul Agrawal Adds More Stake in a Smallcap Pharma Stock

In every field of human endeavour, an elite few shine brighter than the rest. While many fields produce luminaries, few domains offer such clear-cut metrics for greatness as investing.

The realm of finance is a proving ground where fortunes are made and lost, and those who consistently outperform the market are revered as true masters.

These investment titans possess a unique blend of intellect, intuition, and experience that enables them to navigate the complex financial landscape with unparalleled acumen.

Their ability to spot emerging trends, understand the intricate workings of the economy, and make bold, calculated decisions sets them apart.

Countless investors aspire to emulate their success, poring over their strategies in hopes of unlocking the secrets to market-beating returns.

For investors seeking such news, there is noteworthy stock market news: ace investor Mukul Agrawal bought an additional stake in a smallcap pharma firm.

Who is Mukul Agrawal?

Mukul Agrawal is a prominent investor in India, who is known for his microcap stocks and smallcap stock picks.

His style of investment involves a mix of offence and defence.

He follows an offensive strategy for most of the time after proper analysis. He also keeps two separate portfolios for investing and trading.

Which Smallcap Stock Did Mukul Agrawal Buy and Why?

The stock in question is Zota Healthcare.

The company manufactures, markets, and exports pharmaceutical, ayurvedic, nutraceutical, and over-the-counter (OTC) products.

According to the latest shareholding pattern, ace investor Mukul Agrawal increased his stake in Zota Healthcare by an additional 1.5% in the June 2024 quarter, raising his total holding to 8.4%.

In the March 2024 quarter, Agrawal held a 6.8% stake. As of 24 July 2024, his 2.2 million shares are valued at Rs 1.3 billion (bn).

While we do not know why exactly he increased his stake in the company, there are some explanations...

#1 North India Store Expansion

Zota Healthcare's subsidiary, Davaindia on 28 June 2024 announced the grand opening of its newest store in Lucknow.

With the inauguration of this new outlet, Davaindia has significantly strengthened its presence in North India, now boasting 390 stores in the region. Notably, 220 of these stores are situated in Uttar Pradesh, with 25 in Lucknow alone.

The positive reception and growing demand for high-quality generic drugs in Northern India have prompted Davaindia to undertake a significant expansion around Lucknow city.

The company is dedicated to addressing this rising demand and ensuring that affordable healthcare is accessible to everyone.

This store addition can be one of the reasons why ace investor might have added the stake.

#2 Subsidiary's Strong Expansion Plan

Davaindia, a retail generic pharma chain and a business vertical of NSE-listed Zota Healthcare is set to expand its footprint in Bengal, growing from 75 to 200 stores over the next year.

This expansion comes in response to the rising awareness of generic medicines. Currently, Davaindia operates 75 stores in Bengal, 14 of which are company-owned.

The new plan involves a mix of company-owned and franchisee-operated stores, with a national target of reaching 1,000 stores.

Data from the NSE indicates that Davaindia's quarterly gross merchandise value increased from Rs 232.4 million (m) in Q3 2022-23 to Rs 367.4 m in Q3 2023-24.

Alongside the physical store expansion, the company plans to boost its online presence in the coming months.

Davaindia offers a range of generic medicines, including those for diabetic, cardiac, nephro, gastro, and geriatric conditions, and is also expanding to include oncology drugs.

This robust expansion plan for Davaindia may be one reason behind Mukul Agrawal's decision to increase his stake in Zota Healthcare.

#3 Positive Sectoral Outlook

Looking ahead, the Indian pharmaceutical industry is projected to reach US$ 65 bn by 2024, approximately US$ 130 bn by 2030, and US$ 450 bn by 2047.

As the largest global provider of generic drugs, India is renowned for its affordable vaccines and generic medications.

The industry is currently ranked third in pharmaceutical production by volume and has evolved into a thriving sector, growing at a CAGR of 9.43% over the past nine years.

The Indian government has introduced several initiatives to bolster the pharmaceutical sector, including the Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP), the production linked incentive (PLI) scheme for pharmaceuticals, the Promotion of Bulk Drug Parks Scheme, and the Pharmaceutical Technology Upgradation Assistance Scheme (PTUAS).

These positive trends are expected to enhance Zota Healthcare's position within the Indian market.

A Look at Zota Healthcare's Financials

Zota Healthcare has shown strong revenue growth over the past three years. Revenue increased from Rs 1,311.9 in FY22 to Rs 1,804.9 bn in FY24, a compound annual growth rate (CAGR) of 16.6%.

Despite the increase in revenue, the company has faced growing net losses. The net loss decreased from Rs 89.1 m in FY22 to Rs 57.7 m in FY23, indicating some improvement.

However, the net loss widened significantly in FY24 to Rs 143.5 m. This suggests that while revenue is increasing, expenses or operational inefficiencies are impacting profitability.

The net profit margin has deteriorated over the years. In FY22, the company achieved a positive net profit margin of 6.8%. However, the margin turned negative in FY23 at -4.1% and worsened further to -7.9% in FY24.

Zota Healthcare Financial Snapshot (FY22-24)

(Rs m, Consolidated)	FY22	FY23	FY24
Operational Revenue	1,311.90	1,399.60	1,804.90
Growth (%)	-	6.7	28.9
Net loss	89.1	-57.7	-143.5
Net Profit Margin (%)	6.8	-4.1	-7.9

Source: Equitymaster

How Shares of Zota Healthcare have Performed Recently

The share price of Zota Healthcare has gained 19.9% in the past six months.

Over the past one year, shares of the company have gained 33.6%. In 2024, the share price of the company is up 18.5%.

The company touched its 52-week high of Rs 645 on 19 June 2024 and its 52-week low of Rs 372 on 10 October 2023.

About Zota Healthcare

Zota Healthcare is a prominent player in the pharmaceutical industry, specialising in the manufacture, marketing, and export of a diverse range of products, including ayurvedic, nutraceutical, and over-the-counter (OTC) medications.

Founded in Surat, India, the company has established itself as a significant contributor to the healthcare sector, focusing on delivering high-quality, affordable healthcare solutions.

The company is known for its robust portfolio, which spans various therapeutic segments, catering to both domestic and international markets.

In addition to its core pharmaceutical operations, Zota Healthcare is also recognised for its retail chain, Davaindia, which offers a wide array of generic medicines.

Davaindia has been expanding its presence, with a focus on increasing the availability of generic drugs and improving access to affordable healthcare solutions across India.

For more details, see the Zota Health Care company fact sheet and quarterly results.

And to know what's moving the Indian stock markets today, check out the most recent share market updates here.

Disclaimer: This article is for information purposes only. It is not a stock recommendation and should not be treated as such. Learn more about our recommendation services here...